$0.15
-0.01 (-5.10%)
Open$0.16
Previous Close$0.15
Day High$0.16
Day Low$0.15
52W High$13.70
52W Low—
Volume—
Avg Volume3.01M
Market Cap1.98M
P/E Ratio—
EPS$-24.74
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+14,274.1% upside
Current
$0.15
$0.15
Target
$21.13
$21.13
$13.63
$21.13 avg
$23.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.00M | 1.99M | 1.61M |
| Net Income | -74,230 | -69,635 | -62,110 |
| Profit Margin | -3.7% | -3.5% | -3.9% |
| EBITDA | -116,342 | -139,946 | -107,891 |
| Free Cash Flow | -67,743 | -57,560 | -72,298 |
| Rev Growth | +11.8% | +24.3% | -3.3% |
| Debt/Equity | 0.69 | 0.66 | 0.82 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |